Company
Pfizer
Pfizer Inc.
Public (NYSE:PFE) · New York, New York, USA · Last verified Aug 15, 2024
Diversified pharma pursuing oral GLP-1 small molecules for obesity and diabetes.
Company profile
- Legal name
- Pfizer Inc.
- Status
- public
- Ticker
- NYSE:PFE
- Headquarters
- New York, New York, USA
- Website
- www.pfizer.com
Active assets
| Asset | Stage | Indications |
|---|---|---|
| Danuglipron | Phase 2 | — |
Discontinued assets
| Asset | Stage | Indications |
|---|---|---|
| Lotiglipron | Discontinued | — |
Trial roll-up
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT05564117 | Phase 2 | A Study of Danuglipron in Participants With Type 2 Diabetes | Completed |
| Pfizer-lotiglipron-Ph2 | Phase 2 | A Study of Lotiglipron in Participants With Type 2 Diabetes | Terminated |